| アブストラクト | The product monograph for reference bevacizumab (Avastin) and biosimilar bevacizumab (Mvasi) recommend to infuse the first dose of bevacizumab over 90 min, second dose over 60 min and third and subsequent doses over 30 min. Despite the product monograph recommendations, many institutions adopted an accelerated bevacizumab (Avastin) 0.5 mg/kg/min infusion time. Our province adopted the accelerated infusion time at time of biosimilar bevacizumab (Mvasi) adoption. Our experience with the accelerated infusion time was well tolerated in the first five months of biosimilar bevacizumab adoption across different tumor types. |
|---|
| 投稿日 | 2020/7/31 |
|---|
| 投稿者 | Geirnaert, Marc; Howarth, Jacy; Kellett, Curtis; Martin, Kristen; Streilein, Scott; Ricard, Chad; Wasney, Danica; Niraula, Saroj |
|---|
| ジャーナル名 | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners |
|---|
| 組織名 | Provincial Oncology Drug Program, CancerCare Manitoba, Winnipeg, Canada.;Department of Pharmacy, CancerCare Manitoba, Winnipeg, Canada.;Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.;Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg,;Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32727322/ |
|---|
